Alphyn Biologics, Inc.

Alphyn Biologics, LLC (Alphyn) is improving therapies for skin diseases with its patent pending AB-101 biomaterial that has multiple 40 bio-active compounds to target & cure diseases.  The AB-101 biomaterial provides multiple ways to attack each disease, creating & leading the way in Multi-target Therapeutics for a new class of drugs.  AB-101 initial products solve two of the largest medical challenges to humankind - drug resistant infections including MRSA (1st product) & skin diseases made worse by infection.